A citation-based method for searching scientific literature

Esther Conde, Susana Hernandez, Rebeca Martinez, Barbara Angulo, Javier De Castro, Ana Collazo-Lorduy, Beatriz Jimenez, Alfonso Muriel, Jose Luis Mate, Teresa Moran, Ignacio Aranda, Bartomeu Massuti, Federico Rojo, Manuel Domine, Irene Sansano, Felip Garcia, Enriqueta Felip, Nuria Mancheño, Oscar Juan, Julian Sanz, Jose Luis Gonzalez-Larriba, Lidia Atienza-Cuevas, Esperanza Arriola-Arellano, Ihab Abdulkader, Jorge Garcia-Gonzalez, Carmen Camacho, Delvys Rodriguez-Abreu, Cristina Teixido, Noemi Reguart, Ana Gonzalez-Piñeiro, Martin Lazaro-Quintela, Maria Dolores Lozano, Alfonso Gurpide, Javier Gomez-Roman, Marta Lopez-Brea, Lara Pijuan, Marta Salido, Edurne Arriola, Amparo Company, Amelia Insa, Isabel Esteban-Rodriguez, Monica Saiz, Eider Azkona, Ramiro Alvarez, Angel Artal, Maria Luz Plaza, David Aguiar, Ana Belen Enguita, Amparo Benito, Luis Paz-Ares, Pilar Garrido, Fernando Lopez-Rios. J Thorac Oncol 2019
Times Cited: 25







List of co-cited articles
280 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Next-generation Sequencing for ALK and ROS1 Rearrangement Detection in Patients With Non-small-cell Lung Cancer: Implications of FISH-positive Patterns.
Sergi Clavé, Natalia Rodon, Lara Pijuan, Olga Díaz, Marta Lorenzo, Pedro Rocha, Álvaro Taus, Remei Blanco, Joaquim Bosch-Barrera, Noemí Reguart,[...]. Clin Lung Cancer 2019
13
30

Programmed death ligand 1 testing in non-small cell lung carcinoma cytology cell block and aspirate smear preparations.
Bryce Noll, Wei-Lien Wang, Yun Gong, Jun Zhao, Neda Kalhor, Victor Prieto, Gregg Staerkel, Sinchita Roy-Chowdhuri. Cancer Cytopathol 2018
72
12

BRAF Alterations as Therapeutic Targets in Non-Small-Cell Lung Cancer.
Tu Nguyen-Ngoc, Hasna Bouchaab, Alex A Adjei, Solange Peters. J Thorac Oncol 2015
52
12

Diagnostic procedures for non-small-cell lung cancer (NSCLC): recommendations of the European Expert Group.
Manfred Dietel, Lukas Bubendorf, Anne-Marie C Dingemans, Christophe Dooms, Göran Elmberger, Rosa Calero García, Keith M Kerr, Eric Lim, Fernando López-Ríos, Erik Thunnissen,[...]. Thorax 2016
83
12

KRAS-Mutant non-small cell lung cancer: From biology to therapy.
Irene Ferrer, Jon Zugazagoitia, Stephan Herbertz, William John, Luis Paz-Ares, Gerald Schmid-Bindert. Lung Cancer 2018
97
12

PD-L1 expression in non-small cell lung carcinoma: Comparison among cytology, small biopsy, and surgical resection specimens.
Jonas J Heymann, William A Bulman, David Swinarski, Carlos A Pagan, John P Crapanzano, Mehrvash Haghighi, Ladan Fazlollahi, Mark B Stoopler, Joshua R Sonett, Adrian G Sacher,[...]. Cancer Cytopathol 2017
115
12

Cytology Smears in the Era of Molecular Biomarkers in Non-Small Cell Lung Cancer: Doing More With Less.
Maria D Lozano, José I Echeveste, Marta Abengozar, Luis D Mejías, Miguel A Idoate, Alfonso Calvo, Carlos E de Andrea. Arch Pathol Lab Med 2018
30
12

Liquid Biopsy for Advanced Non-Small Cell Lung Cancer (NSCLC): A Statement Paper from the IASLC.
Christian Rolfo, Philip C Mack, Giorgio V Scagliotti, Paul Baas, Fabrice Barlesi, Trever G Bivona, Roy S Herbst, Tony S Mok, Nir Peled, Robert Pirker,[...]. J Thorac Oncol 2018
247
12

Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden.
Matthew D Hellmann, Tudor-Eliade Ciuleanu, Adam Pluzanski, Jong Seok Lee, Gregory A Otterson, Clarisse Audigier-Valette, Elisa Minenza, Helena Linardou, Sjaak Burgers, Pamela Salman,[...]. N Engl J Med 2018
12

Implementing TMB measurement in clinical practice: considerations on assay requirements.
Reinhard Büttner, John W Longshore, Fernando López-Ríos, Sabine Merkelbach-Bruse, Nicola Normanno, Etienne Rouleau, Frédérique Penault-Llorca. ESMO Open 2019
100
12

Mechanisms and clinical activity of an EGFR and HER2 exon 20-selective kinase inhibitor in non-small cell lung cancer.
Jacqulyne P Robichaux, Yasir Y Elamin, Zhi Tan, Brett W Carter, Shuxing Zhang, Shengwu Liu, Shuai Li, Ting Chen, Alissa Poteete, Adriana Estrada-Bernal,[...]. Nat Med 2018
150
12


Consistency and reproducibility of next-generation sequencing and other multigene mutational assays: A worldwide ring trial study on quantitative cytological molecular reference specimens.
Umberto Malapelle, Clara Mayo-de-Las-Casas, Miguel A Molina-Vila, Rafael Rosell, Spasenija Savic, Michel Bihl, Lukas Bubendorf, Manuel Salto-Tellez, Dario de Biase, Giovanni Tallini,[...]. Cancer Cytopathol 2017
33
12

Trastuzumab Emtansine (T-DM1) in Patients with Previously Treated HER2-Overexpressing Metastatic Non-Small Cell Lung Cancer: Efficacy, Safety, and Biomarkers.
Solange Peters, Rolf Stahel, Lukas Bubendorf, Philip Bonomi, Augusto Villegas, Dariusz M Kowalski, Christina S Baik, Dolores Isla, Javier De Castro Carpeno, Pilar Garrido,[...]. Clin Cancer Res 2019
62
12

Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer.
Tony S Mok, Yi-Long Wu, Myung-Ju Ahn, Marina C Garassino, Hye R Kim, Suresh S Ramalingam, Frances A Shepherd, Yong He, Hiroaki Akamatsu, Willemijn S M E Theelen,[...]. N Engl J Med 2017
12

RET-rearranged lung adenocarcinomas with lymphangitic spread, psammoma bodies, and clinical responses to cabozantinib.
Sanjay Mukhopadhyay, Nathan A Pennell, Siraj M Ali, Jeffrey S Ross, Patrick C Ma, Vamsidhar Velcheti. J Thorac Oncol 2014
31
12

Programmed Death-Ligand 1 Immunohistochemistry Testing: A Review of Analytical Assays and Clinical Implementation in Non-Small-Cell Lung Cancer.
Reinhard Büttner, John R Gosney, Birgit Guldhammer Skov, Julien Adam, Noriko Motoi, Kenneth J Bloom, Manfred Dietel, John W Longshore, Fernando López-Ríos, Frédérique Penault-Llorca,[...]. J Clin Oncol 2017
219
12

Ado-Trastuzumab Emtansine for Patients With HER2-Mutant Lung Cancers: Results From a Phase II Basket Trial.
Bob T Li, Ronglai Shen, Darren Buonocore, Zachary T Olah, Ai Ni, Michelle S Ginsberg, Gary A Ulaner, Michael Offin, Daniel Feldman, Todd Hembrough,[...]. J Clin Oncol 2018
142
12

Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer.
Martin Reck, Delvys Rodríguez-Abreu, Andrew G Robinson, Rina Hui, Tibor Csőszi, Andrea Fülöp, Maya Gottfried, Nir Peled, Ali Tafreshi, Sinead Cuffe,[...]. N Engl J Med 2016
12

Interpretive Diagnostic Error Reduction in Surgical Pathology and Cytology: Guideline From the College of American Pathologists Pathology and Laboratory Quality Center and the Association of Directors of Anatomic and Surgical Pathology.
Raouf E Nakhleh, Vania Nosé, Carol Colasacco, Lisa A Fatheree, Tamera J Lillemoe, Douglas C McCrory, Frederick A Meier, Christopher N Otis, Scott R Owens, Stephen S Raab,[...]. Arch Pathol Lab Med 2016
32
12

Screening for epidermal growth factor receptor mutations in lung cancer.
Rafael Rosell, Teresa Moran, Cristina Queralt, Rut Porta, Felipe Cardenal, Carlos Camps, Margarita Majem, Guillermo Lopez-Vivanco, Dolores Isla, Mariano Provencio,[...]. N Engl J Med 2009
12

Aberrant anaplastic lymphoma kinase expression in high-grade pulmonary neuroendocrine carcinoma.
Harumi Nakamura, Koji Tsuta, Akihiko Yoshida, Tatsuhiro Shibata, Susumu Wakai, Hisao Asamura, Koh Furuta, Hitoshi Tsuda. J Clin Pathol 2013
34
12

Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC.
Mark A Socinski, Robert M Jotte, Federico Cappuzzo, Francisco Orlandi, Daniil Stroyakovskiy, Naoyuki Nogami, Delvys Rodríguez-Abreu, Denis Moro-Sibilot, Christian A Thomas, Fabrice Barlesi,[...]. N Engl J Med 2018
12

Targeted Therapy for Patients with BRAF-Mutant Lung Cancer: Results from the European EURAF Cohort.
Oliver Gautschi, Julie Milia, Bastien Cabarrou, Marie-Virginia Bluthgen, Benjamin Besse, Egbert F Smit, Juergen Wolf, Solange Peters, Martin Früh, Dieter Koeberle,[...]. J Thorac Oncol 2015
95
12

Final Overall Survival Analysis From a Study Comparing First-Line Crizotinib Versus Chemotherapy in ALK-Mutation-Positive Non-Small-Cell Lung Cancer.
Benjamin J Solomon, Dong-Wan Kim, Yi-Long Wu, Kazuhiko Nakagawa, Tarek Mekhail, Enriqueta Felip, Federico Cappuzzo, Jolanda Paolini, Tiziana Usari, Yiyun Tang,[...]. J Clin Oncol 2018
146
12

Efficacy of Crizotinib among Different Types of ROS1 Fusion Partners in Patients with ROS1-Rearranged Non-Small Cell Lung Cancer.
Ziming Li, Lan Shen, Ding Ding, Jia Huang, Jie Zhang, Zhiwei Chen, Shun Lu. J Thorac Oncol 2018
37
12

Utilization of ancillary studies in the cytologic diagnosis of respiratory lesions: The papanicolaou society of cytopathology consensus recommendations for respiratory cytology.
Lester J Layfield, Sinchita Roy-Chowdhuri, Zubair Baloch, Hormoz Ehya, Kim Geisinger, Susan J Hsiao, Oscar Lin, Neal I Lindeman, Michael Roh, Fernando Schmitt,[...]. Diagn Cytopathol 2016
34
12

ROS1 immunohistochemistry among major genotypes of non-small-cell lung cancer.
Theresa A Boyle, Katsuhiro Masago, Kim E Ellison, Yasushi Yatabe, Fred R Hirsch. Clin Lung Cancer 2015
37
12

ROS1 rearrangements define a unique molecular class of lung cancers.
Kristin Bergethon, Alice T Shaw, Sai-Hong Ignatius Ou, Ryohei Katayama, Christine M Lovly, Nerina T McDonald, Pierre P Massion, Christina Siwak-Tapp, Adriana Gonzalez, Rong Fang,[...]. J Clin Oncol 2012
968
12

Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
D Planchard, S Popat, K Kerr, S Novello, E F Smit, C Faivre-Finn, T S Mok, M Reck, P E Van Schil, M D Hellmann,[...]. Ann Oncol 2018
351
12

ALK and ROS1 rearrangements tested by fluorescence in situ hybridization in cytological smears from advanced non-small cell lung cancer patients.
Cecilia Bozzetti, Rita Nizzoli, Marcello Tiseo, Anna Squadrilli, Costanza Lagrasta, Sebastiano Buti, Donatello Gasparro, Daniele Zanoni, Maria Majori, Massimo De Filippo,[...]. Diagn Cytopathol 2015
35
12

Detection of ROS1 rearrangement in non-small cell lung cancer: current and future perspectives.
Giulio Rossi, Genny Jocollé, Antonia Conti, Marcello Tiseo, Federica Zito Marino, Giovanni Donati, Renato Franco, Francesca Bono, Francesca Barbisan, Francesco Facchinetti. Lung Cancer (Auckl) 2017
26
12

On the relevance of a testing algorithm for the detection of ROS1-rearranged lung adenocarcinomas.
Lénaïg Mescam-Mancini, Sylvie Lantuéjoul, Denis Moro-Sibilot, Isabelle Rouquette, Pierre-Jean Souquet, Clarisse Audigier-Valette, Jean-Christophe Sabourin, Chantal Decroisette, Linda Sakhri, Elisabeth Brambilla,[...]. Lung Cancer 2014
80
12

Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial.
Alice T Shaw, Enriqueta Felip, Todd M Bauer, Benjamin Besse, Alejandro Navarro, Sophie Postel-Vinay, Justin F Gainor, Melissa Johnson, Jorg Dietrich, Leonard P James,[...]. Lancet Oncol 2017
295
12

Institutional implementation of clinical tumor profiling on an unselected cancer population.
Lynette M Sholl, Khanh Do, Priyanka Shivdasani, Ethan Cerami, Adrian M Dubuc, Frank C Kuo, Elizabeth P Garcia, Yonghui Jia, Phani Davineni, Ryan P Abo,[...]. JCI Insight 2016
200
12

Clinical next-generation sequencing in patients with non-small cell lung cancer.
Ian S Hagemann, Siddhartha Devarakonda, Christina M Lockwood, David H Spencer, Kalin Guebert, Andrew J Bredemeyer, Hussam Al-Kateb, TuDung T Nguyen, Eric J Duncavage, Catherine E Cottrell,[...]. Cancer 2015
138
12

Usefulness of immunohistochemistry for the detection of the BRAF V600E mutation in Japanese lung adenocarcinoma.
Hidefumi Sasaki, Shigeki Shimizu, Yoichi Tani, Masayuki Shitara, Katsuhiro Okuda, Yu Hikosaka, Satoru Moriyama, Motoki Yano, Yoshitaka Fujii. Lung Cancer 2013
31
12

Dichotomous ALK-IHC Is a Better Predictor for ALK Inhibition Outcome than Traditional ALK-FISH in Advanced Non-Small Cell Lung Cancer.
A J van der Wekken, R Pelgrim, N 't Hart, N Werner, M F Mastik, L Hendriks, E H F M van der Heijden, M Looijen-Salamon, A J de Langen, J Staal-van den Brekel,[...]. Clin Cancer Res 2017
43
12

ALK Protein Analysis by IHC Staining after Recent Regulatory Changes: A Comparison of Two Widely Used Approaches, Revision of the Literature, and a New Testing Algorithm.
Antonio Marchetti, Alessia Di Lorito, Maria Vittoria Pace, Manuela Iezzi, Lara Felicioni, Tommaso D'Antuono, Giampaolo Filice, Luigi Guetti, Felice Mucilli, Fiamma Buttitta. J Thorac Oncol 2016
89
12

Safety and Efficacy of Crizotinib in Patients With Advanced or Metastatic ROS1-Rearranged Lung Cancer (EUCROSS): A European Phase II Clinical Trial.
Sebastian Michels, Bartomeu Massutí, Hans-Ulrich Schildhaus, Jeremy Franklin, Martin Sebastian, Enriqueta Felip, Christian Grohé, Delvys Rodriguez-Abreu, Diana S Y Abdulla, Helge Bischoff,[...]. J Thorac Oncol 2019
31
12

Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer.
Jean-Charles Soria, Yuichiro Ohe, Johan Vansteenkiste, Thanyanan Reungwetwattana, Busyamas Chewaskulyong, Ki Hyeong Lee, Arunee Dechaphunkul, Fumio Imamura, Naoyuki Nogami, Takayasu Kurata,[...]. N Engl J Med 2018
12

ROS1 Fusions Rarely Overlap with Other Oncogenic Drivers in Non-Small Cell Lung Cancer.
Jessica J Lin, Lauren L Ritterhouse, Siraj M Ali, Mark Bailey, Alexa B Schrock, Justin F Gainor, Lorin A Ferris, Mari Mino-Kenudson, Vincent A Miller, Anthony J Iafrate,[...]. J Thorac Oncol 2017
53
12

ALK, ROS1 and RET fusions in 1139 lung adenocarcinomas: a comprehensive study of common and fusion pattern-specific clinicopathologic, histologic and cytologic features.
Yunjian Pan, Yang Zhang, Yuan Li, Haichuan Hu, Lei Wang, Hang Li, Rui Wang, Ting Ye, Xiaoyang Luo, Yiliang Zhang,[...]. Lung Cancer 2014
140
12

The new-generation selective ROS1/NTRK inhibitor DS-6051b overcomes crizotinib resistant ROS1-G2032R mutation in preclinical models.
Ryohei Katayama, Bo Gong, Noriko Togashi, Masaya Miyamoto, Masaki Kiga, Shiho Iwasaki, Yasuki Kamai, Yuichi Tominaga, Yasuyuki Takeda, Yoshiko Kagoshima,[...]. Nat Commun 2019
38
12


Targeting NTRK fusion in non-small cell lung cancer: rationale and clinical evidence.
Biagio Ricciuti, Marta Brambilla, Giulio Metro, Sara Baglivo, Roberta Matocci, Matteo Pirro, Rita Chiari. Med Oncol 2017
28
12

Principles of analytic validation of immunohistochemical assays: Guideline from the College of American Pathologists Pathology and Laboratory Quality Center.
Patrick L Fitzgibbons, Linda A Bradley, Lisa A Fatheree, Randa Alsabeh, Regan S Fulton, Jeffrey D Goldsmith, Thomas S Haas, Rouzan G Karabakhtsian, Patti A Loykasek, Monna J Marolt,[...]. Arch Pathol Lab Med 2014
150
12


Repotrectinib (TPX-0005) Is a Next-Generation ROS1/TRK/ALK Inhibitor That Potently Inhibits ROS1/TRK/ALK Solvent- Front Mutations.
Alexander Drilon, Sai-Hong Ignatius Ou, Byoung Chul Cho, Dong-Wan Kim, Jeeyun Lee, Jessica J Lin, Viola W Zhu, Myung-Ju Ahn, D Ross Camidge, Judy Nguyen,[...]. Cancer Discov 2018
136
12

A multicenter study of thromboembolic events among patients diagnosed with ROS1-rearranged non-small cell lung cancer.
Marliese Alexander, Nick Pavlakis, Thomas John, Rachel O'Connell, Steven Kao, Brett G M Hughes, Adrian Lee, Sarah A Hayes, Viive M Howell, Stephen J Clarke,[...]. Lung Cancer 2020
10
30


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.